From:John KaldesSent:Thursday, September 20, 2012 7:37 AMTo:Jason Chung; Michael ClarkeCc:Nancy Baran; Doug PlasscheSubject:RE: DEA follow up to 09/12/12 Suspicious Order Monitoring Presentation

Yes I am available

From: Jason Chung
Sent: Thursday, September 20, 2012 9:56 AM
To: Michael Clarke
Cc: Nancy Baran; Doug Plassche; John Kaldes
Subject: Re: DEA follow up to 09/12/12 Suspicious Order Monitoring Presentation

Nancy/John,

Are you available for the 10th or 11th?

From: Michael Clarke
Sent: Wednesday, September 19, 2012 06:03 PM
To: Jason Chung
Cc: Nancy Baran; Doug Plassche; John Kaldes
Subject: RE: DEA follow up to 09/12/12 Suspicious Order Monitoring Presentation

Jason,

I spoke with Doug about this. I am not available on October 12, since I am traveling with my son for a college visit, but am available most of the rest of that week. Please contact Smilek and ask him to reach out to me for scheduling, but that I am available on October 10 or 11.

Thanks.

Michael

Michael R. Clarke Actavis 973-889-6667 MCLARKE@actavis.com

> From: Jason Chung Sent: Wednesday, September 19, 2012 4:45 PM To: Michael Clarke; Nancy Baran; Doug Plassche; John Kaldes Subject: DEA follow up to 09/12/12 Suspicious Order Monitoring Presentation

$\Delta \pi \text{ EXHIBIT } 12$
Deponentlarke
Date 7/8 Rptr

Michael/Nancy,

I just received a call from NJ Diversion Investigator Michael Smilek, whom you met at the Effective Controls Against Diversion of Controlled Substance presentation last Wednesday. He is requesting a

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER



ALLERGAN\_MDL\_03382548

meeting with Actavis to review our action items as a result of the meeting. His preferred date is October 12<sup>th</sup>.

Jason Chung DEA Manager

3

3



Actavis 200 Elmora Avenue *t* 1-908-659-2982 @ <u>JChung@actavis.com</u> Elizabeth , NJ 07202 United States *w* <u>www.actavis.com</u> Internal VoIP number

Please note that this e-mail and its attachments are intended for the named addressee only and may contain information that is confidential and privileged. If you have by coincidence or mistake or without specific authorization received this e-mail and its attachments we request that you notify us immediately that you have received them in error, uphoid strict confidentiality and neither read, copy, nor otherwise make use of their content in any way Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis Group or its subsidiaries.

ALLERGAN MDL 03382549